NZ244239A - Genetically engineered tyrosine kinase receptors - Google Patents

Genetically engineered tyrosine kinase receptors

Info

Publication number
NZ244239A
NZ244239A NZ24423992A NZ24423992A NZ244239A NZ 244239 A NZ244239 A NZ 244239A NZ 24423992 A NZ24423992 A NZ 24423992A NZ 24423992 A NZ24423992 A NZ 24423992A NZ 244239 A NZ244239 A NZ 244239A
Authority
NZ
New Zealand
Prior art keywords
receptor
signalling
pharmaceutical composition
incompetent
growth factor
Prior art date
Application number
NZ24423992A
Other languages
English (en)
Inventor
Axel Ullrich
Norbert Hugo Redemann
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of NZ244239A publication Critical patent/NZ244239A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ24423992A 1991-09-05 1992-09-07 Genetically engineered tyrosine kinase receptors NZ244239A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914129533 DE4129533A1 (de) 1991-09-05 1991-09-05 Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs

Publications (1)

Publication Number Publication Date
NZ244239A true NZ244239A (en) 1995-07-26

Family

ID=6439926

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ24423992A NZ244239A (en) 1991-09-05 1992-09-07 Genetically engineered tyrosine kinase receptors

Country Status (12)

Country Link
EP (1) EP0667899A1 (sv)
JP (1) JPH07502884A (sv)
CN (1) CN1071586A (sv)
AU (1) AU669857B2 (sv)
CA (1) CA2117073A1 (sv)
DE (1) DE4129533A1 (sv)
FI (1) FI941053A (sv)
MX (1) MX9205084A (sv)
NO (1) NO940778L (sv)
NZ (1) NZ244239A (sv)
PT (1) PT100844A (sv)
WO (1) WO1993005148A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465623B2 (en) 1995-05-02 2002-10-15 Garvan Institute Of Medical Research GDU, a novel signalling protein
AUPN274295A0 (en) * 1995-05-02 1995-05-25 Garvan Institute Of Medical Research GDU, a novel signalling protein
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
ES2741546T3 (es) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (en) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
WO1990008160A1 (en) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Growth factor receptor-like peptides without tyrosine-kinase activity
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
ATE155813T1 (de) * 1989-05-19 1997-08-15 Genentech Inc Her2 extrazellulare domäne
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas

Also Published As

Publication number Publication date
MX9205084A (es) 1993-05-01
CA2117073A1 (en) 1993-03-18
NO940778L (no) 1994-05-04
FI941053A0 (sv) 1994-03-04
EP0667899A1 (de) 1995-08-23
WO1993005148A1 (de) 1993-03-18
CN1071586A (zh) 1993-05-05
AU2518592A (en) 1993-04-05
FI941053A (sv) 1994-04-08
AU669857B2 (en) 1996-06-27
NO940778D0 (no) 1994-03-04
DE4129533A1 (de) 1993-03-11
JPH07502884A (ja) 1995-03-30
PT100844A (pt) 1994-05-31

Similar Documents

Publication Publication Date Title
US5705157A (en) Methods of treating cancerous cells with anti-receptor antibodies
JP5719270B2 (ja) 腫瘍治療のための組成物および方法
EP0865448B1 (en) Apoptosis induced by monoclonal antibody anti-her2
US7138508B2 (en) Inhibitor protein of the wnt signal pathway
EA021867B1 (ru) Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций
EA004793B1 (ru) Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения
Ban et al. Isolation and characterization of a 2.3-kilobase-pair cDNA fragment encoding the binding domain of the bovine leukemia virus cell receptor
CN109810995B (zh) 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
JP3492364B2 (ja) 過剰増殖性細胞の複製阻害方法
JP2001512319A (ja) 細胞のＮＦ−κＢ活性化を調節するための組成物および方法
US20060025362A1 (en) Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
NZ244239A (en) Genetically engineered tyrosine kinase receptors
JPH09505557A (ja) ヒト腫瘍細胞の遺伝子形質転換によるヒト腫瘍の治療
UA75565C2 (uk) Фармацевтична сполука для стимулювання ангіогенезу (варіанти), фармацевтична сполука для інгібування ангіогенезу (варіанти) та спосіб модулювання ангіогенезу з їх використанням
CN100497382C (zh) 突变型Bik的抗肿瘤效果
JP6820123B2 (ja) Ｃｃｌ３変異体を含む融合タンパク質およびその用途
EP0967276A2 (en) Anti-tumor agent comprising salmosin
CA2042605A1 (en) Cytolysis inhibitor proteins (cli), dna sequences coding for said proteins, and plasmids, host organisms, and processes for obtaining said proteins
JP2003507337A (ja) チロシンキナーゼｒａｆおよびｒａｓを用いて脈管形成を調節するために有用な方法および組成物
DK170781B1 (da) Human leukoregulin og biologisk aktive underenheder deraf, fremgangsmåde til fremstilling og til oprensning af human leukoregulin, biologisk aktivt materiale indeholdende human leukoregulin samt celle, som producerer human leukoregulin
CN1948342B (zh) 一种新的候选癌基因hRabJ来源的HLA-A2限制性表位多肽及其应用
JP2697725B2 (ja) 悪性腫瘍治療用キット
BR102013025838A2 (pt) Proteínas de fusão endo-bax e endo-bax-endo e suas sequências de aminoácidos